{
  "docId": "019de077-5130-7668-92cb-6c77396e6bd2",
  "docSlug": "e021a2de9332664c5094197b4bc248cd",
  "documentTitle": "AstraZeneca | Results Presentation Deck | 157 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 37,
  "pageCount": 132,
  "prevPage": 36,
  "nextPage": 38,
  "slideType": "appendix_data",
  "function": "analyze_data",
  "density": "balanced",
  "nDataPoints": 2,
  "notes": "The slide uses a vertical navigation bar on the right to indicate the drug's development stage (Late-stage development) and therapeutic area (Oncology).",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de077-5130-7668-92cb-6c77396e6bd2/37",
  "deckHref": "/decks/019de077-5130-7668-92cb-6c77396e6bd2",
  "deckJsonHref": "/decks/019de077-5130-7668-92cb-6c77396e6bd2.json",
  "deckAnchorHref": "/decks/019de077-5130-7668-92cb-6c77396e6bd2#slide-37",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.03,
        "x": 0.97,
        "y": 0.05
      },
      "kind": "other",
      "text": "Oncology",
      "attrs": null,
      "subkind": "unclassified",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "67bdf931-83e7-494f-812a-8cd9c934bc49",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.94,
        "x": 0.03,
        "y": 0.195
      },
      "kind": "table",
      "text": "Trial: Phase III SOUNDTRACK-F1 NCT06549595; Population: Previously Untreated Follicular Lymphoma; Patients: 1005; Design: Multicentre, Randomised, Open-label Study; Endpoints: Primary endpoint - PFS, Secondary: CR; Status: FPCD: Q3 2024",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4b6b4c59-bb8a-4e3f-8b3b-e901eb760f19",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.75,
        "x": 0.03,
        "y": 0.05
      },
      "kind": "title",
      "text": "AZD0486 (CD19/CD3 next-generation bispecific T-cell engager) Haematologic malignancies",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ea3ea51e-d339-4581-a377-d2147f036e45",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "9331ca62-7a15-4533-a5ff-d261c081bfcd",
      "evidence": "table/data: Trial: Phase III SOUNDTRACK-F1 NCT06549595; Population: Previously Untreated Follicular Lymphoma; Patients: 1005; Design: Multicentre, Randomised, Open-label Study; Endpoints: Primary endpoint - PFS, Secondar",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 120,
      "from": 6,
      "beatId": "0c127c3c-ea10-450c-b057-64b7f7a0f03c",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "Detailed overview of AstraZeneca's pipeline and portfolio",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 40,
      "from": 30,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "dffbb50c-e367-4fbd-9f65-f687fdc06626",
      "evidence": "Discussion of AstraZeneca's scientific approach and goals",
      "position": 1,
      "objective": "Explaining the 'why' behind AstraZeneca's pipeline and portfolio",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.6,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}